You are here

  • Home
  • Archive
  • Volume 25, Issue 6
  • Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study

Article info

Article menu
Download PDFPDF
Ovarian Cancer
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study

Authors

  • Karen Sayal Department of Oncology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom; PubMed articlesGoogle scholar articles
  • Ioannis Gounaris Department of Oncology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom;Cancer Research United Kingdom Cambridge Institute, University of Cambirdge, Li Ka Shing Centre, Cambridge, United Kingdom; PubMed articlesGoogle scholar articles
  • Bristi Basu Department of Oncology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom;Cancer Research United Kingdom Cambridge Institute, University of Cambirdge, Li Ka Shing Centre, Cambridge, United Kingdom; PubMed articlesGoogle scholar articles
  • Sue Freeman Department of Radiology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom; PubMed articlesGoogle scholar articles
  • Penny Moyle Department of Radiology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom; PubMed articlesGoogle scholar articles
  • Karen Hosking Department of Oncology, University of Cambridge, Cambridge, United Kingdom; and PubMed articlesGoogle scholar articles
  • Mahesh Iddawela Department of Oncology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom; PubMed articlesGoogle scholar articles
  • Mercedes Jimenez-Linan Department of Histopathology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom. PubMed articlesGoogle scholar articles
  • Jean Abraham Department of Oncology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom;Department of Oncology, University of Cambridge, Cambridge, United Kingdom; and PubMed articlesGoogle scholar articles
  • James Brenton Department of Oncology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom;Cancer Research United Kingdom Cambridge Institute, University of Cambirdge, Li Ka Shing Centre, Cambridge, United Kingdom; PubMed articlesGoogle scholar articles
  • Helen Hatcher Department of Oncology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom;Department of Oncology, University of Cambridge, Cambridge, United Kingdom; and PubMed articlesGoogle scholar articles
  • Helena Earl Department of Oncology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom;Department of Oncology, University of Cambridge, Cambridge, United Kingdom; and PubMed articlesGoogle scholar articles
  • Christine Parkinson Department of Oncology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom; PubMed articlesGoogle scholar articles
  1. Address correspondence and reprint requests to Christine Parkinson, Department of Oncology, Cambridge University NHS Foundation Trust, Box 193, Hills Rd, Cambridge, CB2 0QQ, United Kingdom. E-mail: christine.parkinson{at}cruk.cam.ac.uk.

Citation

Sayal K, Gounaris I, Basu B, et al
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
International Journal of Gynecologic Cancer 2015;25:977-984.

Publication history

  • Received October 11, 2014
  • Accepted March 8, 2015
  • First published July 1, 2015.
Online issue publication 
February 27, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Copyright © 2015 by IGCS and ESGO